$Minerva Neurosciences(NERV)$Shares of Minerva Neurosciences Inc. soared nearly 73% to $7.81 per share on Wednesday.
After the bell Tuesday, billionaire hedge fund manager Steven Cohen's Point72 Asset Management L.P. disclosed that it has an 8.8% stake in the company.
On Monday, the Minerva's stock closed with a 47.83% gain after it submitted a new drug application with the U.S. Food and Drug Administration for roluperidone as a treatment for patients with schizophrenia.nia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Nice
Ok